Opinion

Video

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Alison Schram, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center
January 2nd 2025

FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Christopher J. Logothetis, MD, of The University of Texas MD Anderson Cancer Center
December 27th 2024

A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology

Renal Cell Carcinoma | stock.adobe.com
December 13th 2024

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC